In the news release, MYOS RENS Technology Announces the Date for
the Release of First Quarter 2018 Results, Conference Call and
Webcast, issued 03-May-2018 by MYOS
RENS Technology Inc. over PR Newswire, we are advised by the
company that the conference call day should read "Thursday, May 10,
2018" rather than "Wednesday, May 10, 2018" as originally issued
inadvertently. The complete, corrected release follows:
MYOS RENS Technology Announces the Date for the Release of First
Quarter 2018 Results, Conference Call and Webcast
CEDAR KNOLLS, N.J.,
May 3, 2018 /PRNewswire/ -- MYOS RENS
Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a
bionutrition company and owner of Fortetropin®, the
natural food product that helps build lean muscle in conjunction
with resistance training, announced today that it will host a
conference call on Thursday, May 10,
2018 at 11:00 am ET, at which
time MYOS Chief Executive Officer, Joseph
Mannello, will provide highlights and commentary on earnings
results and clinical studies' developments for the first quarter
ended March 31, 2018.
The Company will announce earnings results for the first quarter
ended March 31, 2018, prior to the
conference call.
Conference Call
Details:
|
|
Call
Date/Time:
|
Thursday, May 10,
2018 at 11:00 am ET
|
|
|
Call Title:
|
MYOS RENS Technology
First Quarter 2018 Financial Results Conference Call
|
|
|
Dial
In:
|
Inside
U.S.: 877-407-4019
|
|
International:
201-689-8337
|
|
|
|
Please dial
into the conference a few minutes before the call
starts.
|
A digital replay will be available by telephone approximately
two hours after the completion of the call until July 31, 2018 and may be accessed by dialing
877-660-6853 from the U.S. or 201-612-7415 for international
callers, using the Conference ID# 13679724.
The webcast will be available on the MYOS website,
https://ir.myosrens.com/, in the "Investor Relations" section. The
webcast will be archived and available at the same web address for
two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, the world's first clinically-demonstrated
myostatin reducer. Myostatin is a natural regulatory protein, which
inhibits muscle growth. Fortetropin® is a fertilized egg
yolk based product manufactured via a proprietary process to retain
and optimize its biological activity. Fortetropin® has
been clinically shown to increase muscle size and lean body mass in
conjunction with resistance training. MYOS believes
Fortetropin® has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this release that are not historical facts
are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the ability to create
new products through research and development, the successful
results of strategic initiatives, the successful launch of our
products, including Qurr® products, the success
of our research and development, including the clinical studies
described above, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to continue increasing our revenue and gross profit
margins, the ability to achieve a sustainable, profitable business,
the effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-the-date-for-the-release-of-first-quarter-2018-results-conference-call-and-webcast-300642429.html
SOURCE MYOS RENS Technology Inc.